【レポートの概要（一部）】
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Candidiasis Overview 11
Therapeutics Development 12
Pipeline Products for Candidiasis – Overview 12
Pipeline Products for Candidiasis – Comparative Analysis 13
Candidiasis – Therapeutics under Development by Companies 14
Candidiasis – Therapeutics under Investigation by Universities/Institutes 17
Candidiasis – Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Candidiasis – Products under Development by Companies 22
Candidiasis – Products under Investigation by Universities/Institutes 25
Candidiasis – Companies Involved in Therapeutics Development 26
Actavis plc 26
Aureogen Biosciences, Inc. 27
Basilea Pharmaceutica AG 28
Biomar Microbial Technologies 29
Cellceutix Corporation 30
Eisai Co., Ltd. 31
General Biologicals Corporation 32
Grupo Ferrer Internacional, S.A. 33
iCo Therapeutics Inc. 34
Novabiotics Ltd 35
NovaDigm Therapeutics, Inc. 36
Novartis AG 37
Onxeo SA 38
Panacela Labs, Inc. 39
Scynexis, Inc. 40
Sealife PHARMA GMBH 41
Sequella, Inc. 42
Viamet Pharmaceuticals, Inc. 43
Wellstat Vaccines, LLC 44
Candidiasis – Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
AC-17 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
albaconazole – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
amphotericin b – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
arasertaconazole – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AUGC-10 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AUGC-15 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
candida vaccine – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
candidiasis vaccine – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
E-1210 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
E-1211 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
isavuconazonium sulfate – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
miconazole – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
mutanobactins – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
NDV-3 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NDV-3A – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
NP-339 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PAC-113 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
pegylated amphotericin B – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PEV-7 – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
PMX-1408 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PMX-1502 – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
PMX-1570 – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PMX-1576 – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PMX-1591 – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PMX-1625 – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
PMX-30016 – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
PMX-519 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Prof-002 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Peptides for Oropharyngeal Candidiasis – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
SCY-078 – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
SLP-0901 – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
SLP-0904 – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecule for Candidiasis – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule for Candidiasis – Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecule for Candidiasis and Cryptococcosis – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Small Molecule for Cryptococcosis and Candidiasis – Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Small Molecule for Fungal Infections – Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecules for Aspergillosis and Candidiasis – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules for Candidiasis – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules for Candidiasis – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules for Fungal Infections – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
SQ-109 – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
VT-1161 – Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
XELRYX-3 – Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Candidiasis – Recent Pipeline Updates 108
Candidiasis – Dormant Projects 122
Candidiasis – Discontinued Products 125
Candidiasis – Product Development Milestones 126
Featured News & Press Releases 126
Nov 03, 2014: Basilea Reports Granting Of U.S. Orphan Drug Designation To Isavuconazole For The Treatment Of Invasive Candidiasis 126
Oct 16, 2014: Basilea Reports Protocol Amendment Resulting In Earlier Completion Of Isavuconazole Phase 3 Invasive Candidiasis Study 126
Sep 10, 2014: Data for Viamet’s VT-1161 Presented at ICAAC 2014 127
Jul 16, 2014: FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis 128
Jul 10, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Study of VT-1161 in Patients with Moderate to Severe Acute Vulvovaginal Candidiasis 128
Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig 129
Feb 18, 2014: Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161 130
Nov 18, 2013: Cellceutix Identifies PMX-1408 as treatment Gram-Negative and Candida Fungal Infections 130
Nov 18, 2013: Cellceutix Identifies Drug Candidate for Candida Fungal Infections 131
Sep 26, 2013: NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis 132
Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 135
Disclaimer 135
【レポート販売概要】
■ タイトル：カンジダ症(Candidiasis)の治療薬パイプライン動向（2015年上半期版）■ 英文：Candidiasis - Pipeline Review, H1 2015
■ 発行日：2015年1月22日
■ 調査会社：Global Markets Direct
■ 商品コード：GMDHC6028IDB
■ 調査対象地域：グローバル
- カンピロバクター検査の世界市場2015The report presents a detailed analysis of the Campylobacter diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Campylobacter definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals &nb …
- 航空母艦の世界市場2016-2020About Aircraft CarriersAircraft carriers are warships that serve as aquatic airbases, equipped with a full-length flight deck and facilities for carriage, deployment, and recovery of aircraft. It is the ship that projects air power globally, without depending on the local airbases. These vessels are capable of open ocean operations even in rough seas. These ships are equipped with armor and can fi …
- 3D計測器の世界市場：CMM（三次元測定機）、ODS（光デジタイザ及びスキャナー）、VMM（ビデオ測定機器）The 3D metrology is a dimensional analysis method used to measure an object and acquires all surface points of an object including the hidden points such as non-accessible undercuts. This technology is used in the quality control process to ensure the accuracy of manufactured products. 3D metrology is widely being used in automotive, aerospace, energy & power, and other sectors. This report segmen …
- ポータブル超音波装置の世界市場2017-2021ABSTRACTAbout Portable Ultrasound Portable ultrasound devices are imaging devices that utilize echo-enhanced ultrasound waves to aid in medical diagnosis. They are convenient to carry since they are lighter and smaller than conventional ultrasound machines. Portable ultrasound devices can be used at POC and operated on battery power. Portable ultrasound devices include higher computational power a …
- 日本の自動微生物検査市場2014Complete report $8,850. DataPack (test volumes, sales forecasts, supplier shares) $5,700. “Japanese Automated Microbiology Market 2014” is a new analysis of major business opportunities emerging in the Japanese automated microbiology market during the next five years. The report examines key trends, reviews current and emerging assays; analyzes potential applications o …
- 2014年戦略提言：フランスの薬物乱用検査市場This new 260-page report from Venture Planning Group provides a comprehensive analysis of the French drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and market segment for the following assays: Amphetamines,, Antide …
- 世界のLNG産業年鑑2015：大型オンショア液化/再ガス化、浮体式LNG、小型LNG、LNG船If you are part of the Liquefied Natural Gas (LNG) industry, you must have this definitive reference guide. Visiongain’s new 813 page LNG Yearbook 2015 from business intelligence provider visiongain compiles all of the analysis and forecasts from visiongain’s extensive database of LNG Infrastructure projects and industry knowledge of Large Scale Onshore LNG, FLNG, Small Scale LNG and LNG Carriers …
- ZigBee対応照明の世界市場ABSTRACTAbout ZigBee-Enabled Lighting ZigBee is a set of specifications built around IEEE 802.15.4 wireless protocol. IEEE is a non-profit organization, which is engaged in the R&D of electronic devices. The 802 group is involved in network operations and technologies. Group 15 deals in wireless networking technology. Technavio’s analysts forecast the global zigbee-enabled lighting market to grow …
- 2014年戦略提言：ヨーロッパの血液及びフローサイトメトリー市場Complete report $19,700. DataPack (test volumes, sales forecasts, supplier shares) $12,800.SummaryThis comprehensive five-country report contains 450 pages, 160 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the European hematology and flow cytometry markets during the next five years. The report …
- イーコマース（電子商取引）の世界市場2016-2020About E-Commerce E-commerce or online retail refers to web-based buying and selling of products and services. Despite traditional retailing having a significant market share in the global retail market, e-commerce has gained considerable traction in last five years. Within the e-commerce space, the B2C space is the fastest growing segment, which is attracting the interests of global e-commerce sit …
- 医療レポート：Non-Small Cell Lung Cancer (NSCLC)-疫学予測（～2022）EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022 Summary Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world, representing almost 13% of all cancers (Ferlay et al., 2010). NSCLC is the most common type of lung cancer, comprising about 85% of all lung cancers. An estimated 1.37 mill …
- データセンター用IT装置の世界市場：サーバ、ストレージ、ネットワーク製品About data center IT equipment Enterprises build a data center to house IT equipment such as servers, storage, and network infrastructures. A data center also includes virtual and security appliances for business operational purposes. Most of the modern IT infrastructures such as converged infrastructure offered by vendors are designed to support any business environments. However, data center env …
- Next Generation Network Application Market Outlook and Business DriversDeciding where to invest in Next Generation Network (NGN) applications is difficult without key business case analysis. Planning NGN application deployment is difficult without insights into application value to customers, services blending opportunities, or strategies for services migration. This report evaluates two key elements of NGN: Service Delivery Platforms (SDP) and the IP Multimedia Subs …
- 自動車用ダイレクトドライブ モータの世界市場2017-2021ABSTRACTAbout Automotive Direct Drive Motor Electric motor is a machine that converts electrical energy into mechanical energy through the interaction of magnetic field with current. The motor mainly consists of two parts: a rotor and a stator. The motors can be categorized into direct current (DC) motor and alternating current (AC) motor based on the type of current used by the motor. AC motors a …
- 肺炎(Pneumonia)：世界の治験レビュー（2015年上半期版）Pneumonia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Pneumonia Global Clinical Trials Review, H1, 2015" provides an overview of Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the g …
